Form 4: Equillium Director Martha Demski Receives Stock Options
Statement of Changes in Beneficial Ownership
Director Martha J. Demski was granted 70,000 stock options in Equillium, Inc. as part of a standard equity compensation package.
Summary
- Director Martha J. Demski received a grant of 70,000 stock options for Equillium, Inc. (EQ) common stock.
- The options have an exercise price of $2.84 per share.
- The grant date for these options is May 28, 2026.
- The options are set to expire on May 27, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Aligns director interests with long-term shareholder value through equity-based compensation.
Negatives
- Results in potential future dilution of existing shareholders upon exercise of the options.
Risks
- Market volatility could impact the value of the options relative to the exercise price.
- The value of the equity is dependent on the future performance of Equillium's stock price.
Future Outlook
The options vest in twelve equal monthly installments starting May 28, 2026, with full vesting guaranteed by the date of the next annual stockholders' meeting.
Industry Context
StockSavvy.ai notes that equity grants to non-employee directors are a standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.
Comparison to Industry Standards
- The grant of 70,000 options is consistent with typical director compensation packages for small-cap biotechnology firms.
- Vesting schedules tied to annual meetings are a common industry standard to ensure board continuity.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Director Compensation | Grant of 70,000 stock options to Director Martha J. Demski. | 05/28/2026 | Standard alignment of director incentives with company performance. |
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of options in monthly installments.
- Potential exercise of options by the director after vesting.
Key Dates
| Date | Description |
|---|---|
| 05/28/2026 | Grant date of the stock options and date of the earliest transaction. |
| 05/29/2026 | Date the Form 4 was filed with the SEC. |
| 05/27/2036 | Expiration date of the granted stock options. |
Keywords
Equillium, EQ, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.